OA10 CheckMate 078: Patient-Reported Outcomes (PROs) With Nivolumab vs Docetaxel in Advanced Non-Small Cell Lung Cancer (NSCLC)

Wu, Yi‐Long; Chang, Jianhua; Zhang, L.; Tu, Hai‐Yan; Wu, Lin; Feng, J.; Lu, Shun; Zhou, C.; Wang, J.; Mok, T.; Taylor, Fiona; Mossman, B.; Penrod, John R.; Lawrance, R.; Blum, Steven I.; Wang, P.F.; Cheng, Ying

doi:10.1016/j.jtho.2018.10.020

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nivolumab is recommended as a second-line monotherapy for advanced NSCLC. 3 Pembrolizumab is approved for first-line monotherapy of locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation/anaplastic lymphoma kinase (ALK) mutation-negative NSCLC patients with a PD-1/PD-L1 tumor proportion score (TPS) of ⩾1%, first-line treatment with pemetrexed/platinum of metastatic non-squamous EGFR/ALK mutation-negative NSCLC, and first-line treatment with carboplatin and paclitaxel of metastatic squamous NSCLC. 4 Durvalumab is approved for the treatment of non-advanced stage III unresectable NSCLC after concurrent chemo-radiation.…”

Section: Introductionmentioning

confidence: 99%

Research progress in immune checkpoint inhibitors for lung cancer in China

et al. 2021

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) have come to play an increasingly prominent role in the treatment of lung cancer, and some are recommended as a first-line treatment for late-stage non-small-cell lung cancer, either as a monotherapy or in combination with chemotherapy. Accordingly, the indications of Food and Drug Administration-approved ICIs have increased. In this background, China has implemented various policies to encourage and accelerate the marketing of domestic and imported innovative antitumor drugs. Eight ICIs have been approved in China. Among these, four imported programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors have received approval for six indications, and one domestic PD-1 inhibitor has received approval for one indication for lung cancer in 2018. Numerous clinical trials of ICIs for lung cancer are underway in China. This review aims to summarize the recent advances and future directions of ICIs, including PD-1 inhibitors, PD-L1 inhibitors, cytotoxic T lymphocyte-associated antigen-4 inhibitors, bi-specific antibodies, and a novel inhibitor of T-cell immune-receptor with Ig and immunoreceptor tyrosine-based inhibitory motif domains in immunotherapies for lung cancer in China.

show abstract

Section: Introductionmentioning

confidence: 99%